Brazil doubles yellow fever vaccine production capacity
The Oswaldo Cruz Foundation's Institute of Immunobiological Technology (Bio-Manguinhos/Fiocruz) has doubled its production capacity for the yellow fever vaccine, increasing from 60 million to approximately 120 million vials a year.Brazil’s national drug regulator Anvisa authorized the new production capacity this month. This increase was made possible by removing antibiotics from the vaccine formula and optimizing the Active Pharmaceutical Ingredient (API) production process.Rosane Cuber, Bio-Manguinhos' deputy director of quality, informed Agência Brasil this week that the institution has been supplying this vaccine not only to Brazil but also exporting it to over 70 countries through United Nations (UN) agencies.Cuber explained that the viral vaccine's potency is determined by the ...